HEALTHTECH LEADERS AGENDA

Choose your topic ...            Biotech            Healthtech            Medtech

*** 17:40 - 19:40 Wednesday September 13 - Stay with us for the networking reception ***

Healthtech_Leaders_horizontal-1

 

Day 1 – Wednesday, September 13

09:00 LSX Welcome Address

Jade Osei-Tutu, Sr. Conference Director, LSX


09:10 Keynote Panel: Is Data Pharma's Next Blockbuster? Big Pharma’s Global Digital Health Priorities and Strategy 

Having made their way from the basement to the executive suite, technologies like artificial intelligence (AI) and machine learning are now shaping the future of the life sciences industry – and data is the foundation that drives these technologies forward. However, without the right tools to help manage and process it, the best data in the world can quickly become useless. Embracing data is a crucial step on the journey to building a digitally transformed company and evolving your technology strategy across the entire life sciences lifecycle.  Solutions to good data management can help save pharmaceutical companies billions of dollars and significantly improve the time it takes to bring life-saving new drugs to market, but the industry is still fraught with questions when it comes to centralizing, standardizing, and managing data – then transforming that data into action. Four leaders in life science’s data transformation will discuss those questions, addressing the challenges and opportunities that come with employing data to effectively deliver on a patient-centric mission.

  • As the entire industry evolves to embrace patient data, what are healthcare stakeholders getting right? What are they getting wrong? 
  • What are the biggest challenges to centralizing, standardizing, and managing data? How are you tackling those challenges? 
  • Where in the value chain do you see the most opportunity for digital transformation? 
  • How can data-driven technologies drive therapy adoption for the right patients – or offer more meaningful support to those already on a therapy? 
  • What do you see as the next frontier when it comes to data-driven solutions? What are the tools being developed right now that will transform the way we approach healthcare?  
  • What role does AI play in your company’s operations? Where do you see the most potential for healthcare to benefit from the current AI tide? 
Moderator: Martin Gershon, Managing Partner & CIO, Endeavor Venture Fund 
Jane Urban, Vice President, Customer Engagement Operations, Otsuka Pharmaceutical 
Charles Haddad, AVP/Head Product Strategy, Global Digital Health, Eli Lilly
Meghan Dierks
, Chief Data Officer, Komodo Health 

 Martin GershonJane Urban, VP, Head of Data, Digital & Technology for Global Medical and Commercial, TakedaCharles Haddad AVPHead Product Strategy, Global Digital Health, Eli LillyMeghan Dierks, Chief Data Officer, Komodo Health


9:50 Keynote Panel: Achieving Scale and Profitability in Healthtech Businesses

  • What are the best strategies for scaling digital health solutions and accelerating adoption with patients & clinicians?
  • Lessons on building a scalable digital health business model
  • Defining clear value propositions to address customers’ unmet needs
  • Unique economic/ business models to drive profitability and the benefits of multiple revenue streams for a business
  • Collaboration and partnerships with big pharma/ big medtech to help drive growth 
Moderator: Gary Stewart, Managing Director, Techstars 
Chris Wasden, Chief Strategy Officer, Twill Health
Gabriela Perez, Chief Commercial Officer, Big Health
Randall Stanicky, CFO, Click Therapeutics
Chihiro Hosoya, Head of Rx+ Open Business Creation, Astellas Pharma 

Gary Stewart, Managing Director, TechstarsChris Wasden, Head, Happify HealthGabriela Perez, Chief Commercial Officer, Big HealthRandall Stanicky, CFO, Click Therapeutics Chihiro Hosoya, Head of Rx+ Open Business Creation, Astellas Pharma


10:30 Morning Break


11:00 Overcoming the Challenges of Developing Digital Health Products-A Pharma Perspective

  • Transforming how Pharma work and building a connected infrastructure (IT, data science and AI) 
  • Creating an ecosystem of strategic partnerships–from promising tech start-ups to world-leading academic groups 
  • Integrating AI, machine learning and other emerging technologies/ digital products into worldwide innovation 
Moderator:  Joseph Walsh, Market Strategy & Innovation Leader, Komodo Health 
Amir Zur, Executive Director, Head of R&D Digital Health Products, Takeda Pharmaceuticals
Marcy Rudowitz, Associate Director, Global Voice of Customer Program, Moderna 
Georgia Mitsi, President, Carta Health 
Denise Chou, Clinical Lead, Digital Sciences & Translational Imaging, Early Clinical Development, Pfizer 

Joseph Walsh, Market Strategy & Innovation Leader, Komodo Health Amir Zur, Head of R&D, Digital Health, TakedaMarcy Rudowitz, Associate Director, Global Voice of Customer Program, Moderna Georgia Mitsi, Senior Director for Frontier Business, Sunovion PharmaceuticalsDenise Chou, Clinical Lead, Digital Sciences & Translational Imaging, Early Clinical Development, Pfizer


11:40 Designing for Impact - Digital Health Products that Drive Engagement 

The user experience of your digital health product is key to creating sustained engagement and a positive impact on people’s health. No matter how advanced your treatment or technology is, if the product is not designed to be engaging, accessible, user-friendly and to look trustworthy, people simply won’t use it.  Thomas Michalak sets out to dispel the myth of “build it and they will come” in digital health, exploring how digital habits are formed and behaviours are changed, and how strong design builds trust and drives repeat engagement. 

Thomas Michalak, Creative Director, Graphite Digital

Thomas Michalak


12:00 How are New Digital Innovations Revolutionising Clinical Trials?

The era of clinical trials as we known them is coming to an end. The rising costs of running a trial, coupled with the commercial risks of failure, are unsustainable. This disruptive state is driving the adoption of new technologies and catalysing the digital transformation of clinical trials.

  • Discussing the need to increase the efficiency and quality of clinical trials
  • Exploring the benefits of digital innovations in clinical trials
  • Overview of different types of digital innovations being used in clinical trials
  • Challenges and limitations of implementing digital innovations in clinical trials
  • Opportunities for future advancements and growth in the field of digital innovations in clinical trials
Moderator: Martin Gershon, Managing Partner & CIO, Endeavor Venture Fund
John Campbell, Head of Decentralized Trials, Walgreens Boots Alliance 
John Wagner, CMO, Koneksa 
Pirinka Georgiev Tuttle, Associate Director, Clinician, Digital Sciences, Early Clinical Development, Pfizer 
Kyle Tretina, Alliance Manager, AI Platforms, Insilico Medicine 

Martin Gershonohn Campbell, Head of Decentralized Trials, Walgreens Boots Alliance John Wagner, CMO, Koneksa Pirinka Georgiev, Associate Director, Clinician, Digital Medicine, Early Clinical Development, Pfizer Kyle Tretina, Alliance Manager, AI Platforms, Insilico Medicine


12:45 Lunch Break


13:45 Driving Greater Adoption of Digital Therapeutics into Healthcare Systems

This discussion will focus on what happens once effective DTx is solution built and clinically validated, how do we get it into the hands of those that need it the most? Hear the lessons learned from healthcare leaders on the forefront of the digital therapeutics’ revolution.

  • What challenges are DTx companies facing with integration and adoption into health systems?
  • Lessons learned from scaling digital health tools within large integrated delivery networks
  • Maximizing your chances for success; What needs to be true for your solution, offering and value proposition?
Moderator: Sizi Chen, Product Partner, FoundersX Ventures 
Pierre Leurent, President, Aptar Digital Health
Andy Molnar, CEO, Digital Therapeutics Alliance
Jonathan Schremp, Director of Digital Health Engagement, Banner Health 

Sizi Chen, Product Partner, FoundersX Ventures Pierre Leurent, President, Digital Health, Aptar PharmaAndy Molnar, CEO, Digital Therapeutics AllianceJonathan Schremp, Director of Digital Health Engagement, Banner Health


14:40 Creating Successful Digital Health-Pharma Partnerships and Collaborations  

  • Partnering with Pharma – What are pharma looking for? 
  • The need for new collaboration models  
  • Overcoming roadblocks in digital health/DTx-pharma partnerships and collaborations 
  • How to create a win-win between big pharma, digital health and DTx companies  
  • How to implement AI, machine learning and other emerging technologies into worldwide innovation 
Moderator: Ameya Phadke, Patient Non-Pharma Solutions Leader, Chiesi  
Gregg Talbert, SVP, Head of Personalized Healthcare and Digital Partnering, Roche  
Hassan Naqvi, Head- Digital Health Partnerships, AstraZeneca 
Dan Drozd, Chief Medical Officer, Picnic Health 
Michael Macdonnell, Global Head of Healthcare, Huma 
Michael Pace, CEO & Founder, PalmHealthCo 
Ameya Phadke, Patient Non-Pharma Solutions Leader, Chiesi  Gregg Talbert, SVP Head of Personalised Healthcare and Digital Partnering, RocheHassan Naqvi, Head- Digital Health Partnerships, AstraZeneca Dan Drozd, Chief Medical Officer, Picnic Health Michael Macdonnell, Global Head of Healthcare, HumaMichael Pace, CEO & Founder, PalmHealthCo

15:30 Afternoon Break


16:00 Revolutionizing Healthcare - Exploring New Applications of AI/ML 

How are we using data technology and advanced analytics (artificial intelligence, machine learning, and deep learning) to advance our understanding of disease and deliver breakthroughs that change patients' lives?

  • Overview of how AI/ML is currently being used in healthcare and the potential it holds for the future  
  • 2023 update on Generative and Responsible AI 
  • Glimpsing future use of applications in 10 years. 

Moderator: Geof Hannigan, Executive Director & Co-Founder, Merck Digital Sciences Studio
Neil Sahota, United Nations Artificial Intelligence Advisor & CEO, ACSILabs
Daniel-Adriano Silva, CEO & Co-Founder, Monod
Lana Feng, Founder & CEO, Huma.AI 
Stacie Calad-Thomson, Chief Strategy Officer & Head of Drug Discovery, BioSymetrics 

Geof Hannigan, Executive Director & Co-Founder, Merck Digital Sciences StudioNeil Sahota, United Nations Artificial Intelligence AdvisorDaniel-Adriano Silva, CEO & Co-Founder, Monod  Lana Feng, Founder & CEO, Huma.AI Stacie Calad-Thomson, Chief Strategy Officer & Head of Drug Discovery, BioSymetrics


16:40 Fireside Chat: Driving Growth, Innovation, and Investment in Women’s Health  

Discussing the dynamics in the Women’s Health space, drivers in the market, the vision for the growth of technology innovations in women’s health, and how do we as a sector plan to empower women globally? 

  • Where are we at on the road to solving the funding, medical research, and adoption gaps in women’s health?  
  • An insight into big MedTech's women’s health growth strategy  
  • What are the uncracked spaces? What are the crowded spaces? 
  • Going to market in the US - are there preferred enterprise routes? Is there a playbook? 
Moderator: Jenny Fernandez, Director of Communication & Leadership, Endeavour Venture Fund 
Sapna Rao, Head of Consumer Strategy for Women’s Health, Philips 
Elizabeth Bailey, Managing Director, RH Capital 

Jenny Fernandez, Director of Communication & Leadership, Endeavour Venture Fund Sapna Rao, Head of Consumer Strategy for Women’s Health, PhilipsElizabeth Bailey, Managing Director, Rhia Ventures 300x


17:00 Panel: Playing the Long Game-Healthtech Investment, Deals and Dollars

Due to the complexities within health technology and the health system’s complex regulation, it can be argued that a truly long-term approach is required from partners and investors. Despite the dip in digital health funding in 2022, the potential for long-term success in the healthtech space remains very real with the right strategies in place. This session will discuss the growth in partnerships with venture capital firms, the changing funding environment, and what healthtech investment activity in 2023 looks like so far.

  • An overview of the healthtech investment activity over the past year (investments, valuations and exit trends)
  • Is the Healthtech IPO window still shut?
  • A look into M&A opportunities and trends
  • The importance of healthtech companies demonstrating real value, demonstrating a path to profitability and scalable unit economics
  • Notable transactions and growing digital health companies in Europe and US
  • What’s next for healthtech funding, finance and investment?
Moderator: Jake Gatof, Partner, Wilson Sonsini  
Vishal Gulati, Managing Director, Recode Ventures
Sizi Chen, Product Partner, FounderX Ventures 
Richard Wilmot, Partner, Gilde Healthcare 
Tunde Akinniranye, Investor, 7wire Ventures 

Jake Gatof, Partner, Wilson Sonsini  Vishal GulatiSizi Chen, Product Partner, FoundersX Ventures Richard Wilmot, Head, Philips Health Tech VenturesTunde Akinniranye, Investor, 7wire ventures


17:40 Drinks Reception

Day 2 – Thursday, September 14

09:00 LSX Welcome Address

Jade Osei-Tutu, Sr. Conference Director, LSX


09:10 Keynote Presentation: Remote Monitoring and the Future of Connected Care

The pandemic underscored the need for connected healthcare, especially for patients who needed to be monitored closely in lower acuity areas of care in the hospital and at home after hospital discharge. There is a continued, growing need and market for remote care, particularly for patients who are transitioning from higher to lower acuity settings and home. The current Medtronic Patient Monitoring business, with a portfolio of hundreds of products and $1.4B in annual revenue, is helping drive development of innovative solutions that improve patient outcomes, reduce healthcare costs, and expand patient access to care–both in and out of the hospital. With the help of advanced technology, remote patient monitoring technologies aim to support patients where they have typically not been well-monitored in low acuity areas of care in the hospital and after they are discharged from the hospital, while also alerting providers to potentially critical changes in their patients' health.

James Mault, CEO, BioIntelliSense 

James Mault, CEO, BioIntelliSense


09:30 Making Sense Of Device Data: Helping Clinicians Take Action With Their Patients

The sophistication of today's patient monitoring technologies has allowed healthcare providers to gain new insights into a patient's condition. While this information has been a game-changer in patient care, the burden of multiple datasets from different sources can cause confusion and can overwhelm providers. How can device makers and digital health companies leverage the power of electronic health records (EHRs) (interconnectivity) and AI to make sense of this information and make it more actionable for clinicians?

  • How can device makers and digital health companies leverage the power of electronic health records (EHRs) (interconnectivity) and AI to make sense of this information and make it more actionable for clinicians?  
  • The importance of access and equity to care  
  • Using AI to optimize remote patient monitoring 
Moderator: Ben Linville-Engler, Chief Investment Strategist & Program Executive, MassTech 
Jason Case, VP, R&D - Patient Monitoring, Medtronic 
Russ Johannesson, CEO, Glooko
Nick Wilson, General Manager, Ambulatory Virtual Care, Philips 
Reetta Arokoski, Head of the Life Sciences and Data Partnerships, Elekta 

Ben Linville-Engler, Chief Investment Strategist and Program Executive, Massachusetts Technology CollaborativeJason Case, VP Vice President, R&D - Patient Monitoring, Medtronic Russ Johannesson, CEO, Glooko 300xNick Wilson, General Manager, Ambulatory Virtual Care, Philips Reetta Arokoski, Head of the Life Sciences and Data Partnerships, Elekta


10:20 Morning Break


11:00 Value-Based Care and the Future of Health

  • Discussing why shifting the incentive from volume to quality of care and value for patients is the future for providers, patients and society at large
  • Exploring how digital health start-ups play a role in this system, alongside incumbents, to drive up quality and specificity of care, and drive down user friction
  • How is value-based care crucial to addressing inequities and inefficiencies in the healthcare system?
Moderator: Matt Wetzel, Partner, Goodwin Procter 
Corbin Petro, CEO & Co-Founder, Eleanor Health 
Jeffrey Scott, President & Chief Medical Officer, Integra Connect 
Randy Hawkins
, Chief Medical Officer, Transcarent
Chevon Rariy, Chief Health Officer and SVP Digital Health, Oncology Care Partners  

Matt Wetzel, Partner, Goodwin Procter Corbin Petro, CEO & Co-Founder, Eleanor Health Dr Jeffrey Scott, President and Chief Medical Officer, Integra ConnectRandy Hawkins, Chief Medical Officer, TranscarentChevon Rariy, Venture Partner, Takeda Digital Ventures


11:50 Moving Mental Health into the Mainstream-Scaling Behavioural Healthtech

  • What are the key challenges in scaling mental health start-ups?
  • Creating a sustainable business model for mental healthtech
  • Navigating the regulatory landscape for behavioural healthtech products and services
  • Maximising the potential of strategic partnerships for scaling mental health innovations
  • Exploring evidence-based approaches to mental healthtech innovation
Moderator: Rachel Ford Hutman, CEO, Ford Hutman Media 
Enrico Picozza,Partner, HLM 
Nawal Roy
, Founder & CEO, Holmusk 
Margaret Malone, Principal, Flare Capital Partners 

Rachel Ford Hutman, Founder and CEO Hutman Media 300xEnrico Picozza, Partner, HLM Venture PartnersNawal Roy, Founder & CEO, HolmuskMargaret Malone, Principal, Flare Capital Partners


12:40 Lunch Break


14:00 Unlocking the Potential of Real-World Evidence and Real-World Data in Healthcare

  • Understanding the key challenges hindering the integration of real-world evidence (RWE) and real-world data (RWD) into healthcare
  • How can we overcome the main barriers to RWE/RWD use? (data quality, privacy and regulatory issues)
  • Connecting real world data to clinical trial data
  • Discussing the opportunities that RWE/RWD can bring to healthcare (more personalized treatments, improved patient outcomes and reduced costs)
  • Examining case studies of successful RWE/RWD integration in healthcare
Moderator: Lynn Kasper, Vice President, Strategic Development & Partnerships, Huma.AI 
Sujay Jadhav, CEO, Verana Health
Everett Crosland, Chief Commercial Officer, Cognito Therapeutics 
Michael Pace, CEO & Founder, PalmHealthCo 
Arnaub Chatterjee, Chief Product & Solutions Officer, TriNetX 

Lynn Kasper, Vice President, Strategic Development & Partnerships, Huma.AI Sujay Jadhav, CEO, Verana HealthEverett Crosland, Chief Commercial Officer, Cognito Therapeutics Michael Pace, CEO & Founder, PalmHealthCo  Arnaub Chatterjee, Chief Product & Solutions Officer, TriNetX


14:40 Best Practice when Launching and Running a Digital Therapeutic Clinical Trial

  • Outlining best practices for digital therapeutics clinical trials and randomised controlled trials (RCTs)
  • What are your options when running a clinical trial and are decentralized trials the next best thing?
  • How can you generate high quality RWE with your digital therapeutic and how can you demonstrate value?
  • What evidence is considered ‘good’ from a digital therapeutic clinical trial and how can you best present these for both reimbursement and regulatory approval?
Moderator: René Bastón, VP Strategic Alliances, Team8 Health 
Alankar Gupta, VP, Clinical Development & Medical Affairs, Click Therapeutics
Jess Lake, Director of Medical Affairs, Big Health
Eliane Boucher, Senior Director of Behavioural Science, Twill Health 
Rebecca Miksad, Head of Research Unit, Senior Medical Director, Flatiron 

René Bastón, VP Strategic Alliances, Team8 Health Alankar Gupta, VP, Clinical Development & Medical Affairs, Click TherapeuticsJessica Lake, Chief Science Officer, Limbix-1Eliane Boucher, Senior Director Behavioural Science, Twill Health Rebecca Miksad, Head of Research Unit, Senior Medical Director, Flatiron


15:20 The CVC Playbook-Where are CVCs Placing their Bets?

  • Understanding what CVCs are looking for in when looking to invest in digital health innovators
  • What factors are driving your investment decisions, and which areas are primed for growth?
  • How do you strike a balance between strategic and financial interests?
  • Assessing the current valuation environment
Moderator: Gaye Bok, Partner, Artificial Intelligence and Digital Innovation Fund, Mass General Brigham 
Dave Schulte, SVP & Managing Director, McKesson Ventures
Vijay Jun Patel, Co-Founder & Managing Partner, CVS Health Ventures 
Cris De Luca, Partner, Digital, Sanofi Ventures 

Gaye Bok, Partner, AI and Digital Innovation Fund, Mass General BrighamDave Schulte, SVP & Managing Director, McKesson VenturesVijay Jun Patel, Co-Founder & Managing Partner, CVS Health Ventures Cris de Luca, Global Head, Digital Investments, Sanofi Ventures


16:00 Close of Congress

Company Showcases


REGISTER TO SHOWCASE

Day 1 – Wednesday, September 13

 

11:00 _Scailyte - 300 150

 

11:15 _Solenic Medical - 300 150

 

 

11:30 ARC Medical Logo

 

11:45 Parallel Bio - 300 150

 

12:00 BioCorteX

 

12:15 _WellnessWits  - 300 150

 

12:30 Mediloom (1)

 

LUNCH  
13:45 Tibaray - 300 150

 

14:00 VesiFlo  150 300

 

14:15 Almaden Genomics - 300 150

 

14:30 ThoraGenix 150 300

 

14:45 DermaSensor

 

15:00 Sonic Incytes 300 150

 

15:15 Theradaptive 300 150

 

BREAK  
16:00 Vesteck 300 150

 

16:15 Image Navigation 300 150

 

16:30 GFR90 300 150

 

16:45 Modicus Prime 300 150

 

17:00 Pathkeeper Medical 300 150

 

17:15 Sinaptica Therapeutics 300 150

 

 

Day 2 – Thursday, September 14
 
11:00 iThera Medical 
11:15 FluidForm 150 300

 

11:30 PulseThera 150 300

 

11:45 AWAK 150 300

 

 

 
 

LSX Healthtech CEO Forum-1

Day 2–Thursday, September 14th- 11:00

 

11:00 Welcome Introductions


11:05 Equitable AI: Generating Inclusive AI Healthcare Models

The rapid growth of AI tools in healthcare offers both opportunities and challenges for diversity and equity. To ensure inclusivity, companies are addressing diversity and bias in their models, and government agencies are seeking public input to eliminate bias. Principles and guidelines are being developed to prioritize equity without stifling innovation, and patient privacy is carefully considered. Training AI models at a granular level account for cultural, social, and clinical differences among populations, fostering equitable AI in healthcare while promoting progress.

Wendy Chow, Of Counsel, Morrison Foerster
Brigid Bondoc, FDA, Partner, Morrison Foerster

Wendy Chow, Of Counsel, Morrison Foerster Brigid Bondoc, FDA, Partner, Morrison Foerster


11:25 HealthTech's Multifurcation Challenge: Accurately Representing Diverse Population Segments and Building Heterogeneous Data from Homogeneous Areas

This discussion tackles how companies can accurately represent diverse population segments with ongoing privacy concerns, biases, and data silos. With the building of heterogeneous data from homogenous areas hindering inclusive AI models, overcoming these hurdles demands collaboration, innovative data collection, and ethical considerations for equitable healthcare advancements.

Neil Sahota, CEO, ACSILabs

Neil Sahota, United Nations Artificial Intelligence Advisor


11:45 Why AI Ventures Are Bucking Investment Trends?

Despite the decline in global venture funding in early 2023, AI remains an appealing investment opportunity. From the perspective of an investor, will this interest remain, and how can healthtech companies access this rush in funding?

Martin Gershon, Managing Partner & CIO, Endeavor Venture Fund
Gary Stewart, Managing Director, Techstars

Martin GershonGary Stewart, Managing Director, Techstars


12:05 General Discussion & Closing Remarks


12:15 End of Forum

 

LSX Pharma Digital Leaders Forum (new)

Day 1–Wednesday, September 13th - 16:00

Exclusively for CDOs/CTOs/Global Heads of Digital/Digital Health/Digital Transformation and at top 50 Big Pharma companies, the Pharma Digital Leaders Forum is the regular meeting place for those driving the digitisation at the world's largest pharma companies.

The Forum is intimate, exclusive and attendance is by invitation-only. 

Co-hosted by:

Deloitte Logo

16:00 Welcome Introductions


16:10  Evaluating the Digital Shift in the Pharma Sector

Digital transformation continues to be a critical strategic imperative for the pharma industry.  As companies continue to build and mature digital capabilities there is an increasing importance placed on business value, impact and ROI.  Given this and the current economic and environmental factors, pharma companies are now faced with choices about where to focus their digital efforts and how much effort to place on execution vs innovation.  Clearly there needs to be a portfolio of initiatives that address both, but where is the greatest potential for value?  During this session, we will explore the notion of whether companies should be more execution or innovation focused and why.  Specifically, we will discuss the following types of questions:

  • How much of your digital transformation is spent on execution vs innovation?  How much should be?
  • Are these priorities set top down or bottom up?  How much of it is global vs local?
  • What are the main areas of focus from an Execution vs Innovation perspective?  What others should be?
  • What is the organization better at doing and why?  What could help overcome some of the challenges that exist?

Jonathan Fox, Digital Strategy & Innovation, Deloitte

Jonathan Fox, Managing Director – Life Sciences, Deloitte


16:40 Where Is The Digital Health Ecosystem Headed?

Hassan Naqvi, Head of Digital Health Partnerships, AstraZeneca

Hassan Naqvi, Head- Digital Health Partnerships, AstraZeneca


16:55  Leveraging AI & Machine Learning: Raising Confidence in Public Health and Improving Health Outcomes

Marcy Rudowitz, Associate Director, Global Voice of Customer Program, Moderna

Marcy Rudowitz, Associate Director, Global Voice of Customer Program, Moderna


17:10 General Discussion & Summary of Roundtable


17:30 End of Forum

LSX IPO Workshop

Day 2- Thursday, September 14th - 11:00am

LSX’s IPO Workshop offers executives the chance to exchange ideas with and seek advice from experts in an interactive group setting. They are an opportunity to unpack key processes, procedures and KSFs to a successful listing and considerations for other routes public.

 

IPO Workshop: “3 Ps” of Going Public – Preparation, Path, and Post Transaction

For companies, founders, and entrepreneurs considering entrance into the public markets, this session will focus on the “3 Ps” of going public – preparation, path, and post-transaction; and the different ways to go public in challenging markets. Are you and your board prepared?  What path is most appropriate for you: traditional or an alternative ‘going public avenue. How can you best prepare for success post-transaction?

John Rudy, Member, Mintz

John Rudy, Member, Mintz

Co-hosted by:

Mintz Logo  

 

LSX IP Workshop

Day 2- Thursday, September 14th - 2:00pm

LSX’s IP Workshop offers executives the chance to hear from experts and get the right advice and best practice from experts on the critical consideration of IP. The workshop will provide a guide to intellectual property in life sciences and robustly protecting innovation.

Essential Guide to Intellectual Property in Life Sciences Transactions and Protecting Medicines

  • Building a Desirable Intellectual Property Estate to Support Business Transactions and Protect Medicine
  • Freedom to Operate - Timing and Scope of Patent Landscape Analysis and How to Handle FTO Issues
  • Leveraging Your IP in Life Sciences Transactions
  • Pre-Diligence Preparations - Self Audit, Secure Strategic IP, Point Person, Construct the IP Narrative and Data Room
  • Structuring the IP Diligence - Framework (Establish Framework for the IP Diligence) and Common Concerns
  • Handling Contract Terms Relating to IP - Term Sheet, Scope of Licensed/Sold Technology, Representations and Warranties, Indemnity, Common Issues in License Transactions and Academic spin-outs

Chad E. Davis, Ph.D., Partner, Dechert

Chad E. Davis, Ph.D., Partner, Dechert


Hosted by:

Dechert Logo